CUV

CLINUVEL provided a clinical roadmap update for SCENESSE® in vitiligo, confirming CUV105 (210 patients, darker skin types) will report in December 2026, followed by pivotal CUV107 (300 patients) starting November 2026. The program targets repigmentation via afamelanotide plus narrowband UVB, leveraging SCENESSE®'s existing EPP approval to accelerate future vitiligo regulatory submissions.

CLINUVEL is relocating HQ and cutting 10–20% of workforce to reposition as a U.S.-focused specialty pharma, citing valuation arbitrage (ASX vs. Nasdaq multiples) and deeper capital access. The move formalises existing shareholder composition (66% foreign) and operationalizes a pipeline (vitiligo, photomedicine) already targeted at U.S. markets.

SCENESSE® achieves its fourth major regulatory approval, completing North American + European authorization after two decades of clinical safety data (21,000+ doses). This validates the world's first systemic photoprotective drug for rare EPP and unlocks an established Canadian treatment network, though the ultra-rare disease footprint (~140k per capita) limits near-term revenue scale.